It is one of the most contentious issues in U.S. politics today: the federal health-care law’s requirement that everybody have health insurance or pay a penalty.
Supporters of the mandate—which is the central issue in the case before the Supreme Court challenging the law—argue that it’s the key to making health care more affordable and accessible to everyone. By expanding the pool of insured, the thinking goes, the burden of paying for the sick is covered by all.
In a randomized phase 2 study of patients with metastatic breast cancer, peripheral neuropathy was less likely to occur in patients receiving eribulin mesylate than with ixabepilone.
“Peripheral neuropathy is a big problem in the treatment of breast cancer. Across the spectrum, patients have it, and we don’t know how to treat it,” said Linda T. Vahdat, MD, Weill Cornell Medical College in New York, who presented the study at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.
A quality-of-life analysis of the large randomized NCIC MA. 27 trial shows that symptoms of endocrine therapy can be severe and have a negative effect on quality of life. The study also found that women with side effects from previous chemotherapy or radiotherapy before they start taking endocrine therapy are at higher risk for early discontinuation. Read More ›
To sign up for our newsletter or print publications, please enter your contact information below.